Bridgebio Oncology Therapeutics, Inc. (BBOT)
1.81
-0.05
(-2.69%)
USD |
NASDAQ |
Nov 20, 10:35
Bridgebio Oncology Therapeutics Cash from Operations (Quarterly) : -28.36M for Sept. 30, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | -28.36M |
| June 30, 2026 | -44.36M |
| March 31, 2026 | -35.92M |
| December 31, 2025 | -42.23M |
| September 30, 2025 | -70.63M |
| June 30, 2025 | -23.29M |
| Date | Value |
|---|---|
| March 31, 2025 | -19.60M |
| December 31, 2024 | -15.04M |
| September 30, 2024 | -39.34M |
| June 30, 2024 | -0.0291M |
| March 31, 2024 | -0.618M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Korsana Biosciences, Inc. | -46.83M |
| IRulya Therapeutics, Inc. | -9.84M |
| PepGen Inc. | -13.18M |
| Q32 Bio, Inc. | -4.418M |
| Oncolytics Biotech, Inc. | -6.754M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | 50.34M |
| Cash from Financing (Quarterly) | 0.442M |
| Free Cash Flow | -151.03M |
| Free Cash Flow Per Share (Quarterly) | -0.3539 |
| Free Cash Flow to Equity (Quarterly) | -28.24M |
| Free Cash Flow to Firm (Quarterly) | -28.38M |
| Free Cash Flow Yield | -104.0% |